RxDoctor Payments DataLook up a doctor →

Hamid Salam, MD

Interventional Cardiology · Covington, LANPI 1346287737

Payments from drug & device makers

$52,912in general payments, 2019–2025

Across 582 payments — averaging $90.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$23K
  • Medtronic$12K
  • Edwards Lifesciences$4K
  • Boston Scientific$3K
  • Abbott$3K
  • Abiomed$2K
  • plus $6K from 36 others

What the payments were for

  • Speaking & faculty fees$19,35037%
  • Travel & lodging$15,50329%
  • Food & beverage$18,05934%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,912 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$194,538
Medicare patients
346
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$170,776
EntrestoSacubitril/Valsartan59$74,394
Repatha SureclickEvolocumab74$60,143
JardianceEmpagliflozin38$42,923
FarxigaDapagliflozin Propanediol19$24,316
OzempicSemaglutide27$23,611
XareltoRivaroxaban21$15,982
Praluent PenAlirocumab25$15,513
ClopidogrelClopidogrel Bisulfate350$3,255
Rosuvastatin Calcium267$3,144
Metoprolol Succinate271$2,780
Valsartan77$2,211
Ezetimibe90$2,102
Dofetilide16$1,682
Atorvastatin Calcium177$1,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$170,776141 claims
NovartisEntresto$220$74,39459 claims
Boehringer IngelheimJardiance$17$42,92338 claims
AstraZenecaFarxiga$14$24,31619 claims
Novo NordiskOzempic$73$23,61127 claims
Johnson & JohnsonXarelto$29$15,98221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →